Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
- New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning
Naloxone, the active ingredient in NARCAN® Nasal Spray, is a medication designed to rapidly reverses the effects of an opioid poisoning and is the standard of care for opioid overdose reversal. It is available over the counter and can be accessed at leading pharmacies and grocery stores nationwide, as well as online retailers.
“More than 100,000 people lost their lives to drug overdoses in 2023, and a majority were caused by opioids and synthetic opioids like fentanyl,” said
“Through our Ready to Rescue initiative I’ve had the opportunity to meet so many people who want to step up and help in an opioid emergency; they just need the information and tools to do so,” said
Emergent partnered with
“We are proud partners for this campaign and thrilled with Emergent’s willingness to sponsor this educational initiative,” said
Learn more about the Ready to Rescue campaign and how to perform the ‘Lay, Spray, Stay’ method in an opioid emergency at www.readytorescue.com.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
References:
Centers for Disease Control and Prevention . Statement fromCDC Chief Medical Officer Dr.Deb Houry on 2023 Overdose Death Data. Available at: https://www.cdc.gov/media/releases/2024/s-overdose-data.html. AccessedJuly 19, 2024 .Centers for Disease Control and Prevention . Drug Overdose Data.National Center for Health Statistics , National Vital Statistics System. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. AccessedJuly 19, 2024 .
A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/2719b01f-2640-4af6-be4a-f72a55334667
Source: Emergent BioSolutions